# What two Alzheimer’s trials found about oral semaglutide

- Article ID: research-156
- Product: GLP-1 SEMA (glp-1-sema-687, glp-1-sema-688)
- Canonical page: https://heritagebiolabs.com/research-library/articles/156-what-two-alzheimers-trials-found-about-oral-semaglutide
- Product collection: https://heritagebiolabs.com/research-library/products/glp-1-sema
- Product page: https://heritagebiolabs.com/product/glp-1-sema-687
- Product page: https://heritagebiolabs.com/product/glp-1-sema-688
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short amino-acid chains joined by peptide bonds. By activating receptors, some can influence how cells respond to signals throughout the body. Semaglutide is a modified GLP-1 receptor agonist. Researchers investigated whether its oral form could slow progression in people with early symptomatic Alzheimer’s disease. Two phase 3 trials reported in 2026 compared it with placebo. [1]

The trials were called evoke and evoke+. Together they randomized 3,808 adults aged 55 to 85 with amyloid-confirmed Alzheimer’s disease and either mild cognitive impairment or mild dementia related to it. The two trials used a similar design, and evoke+ also allowed people with significant small-vessel disease in the brain. That design allowed investigators to examine related populations using the same main clinical measure. [1]

The primary outcome was change on the Clinical Dementia Rating Sum of Boxes over 104 weeks. This scale combines assessments of cognition and everyday function. In evoke, scores worsened by an average of 2.3 points with semaglutide and 2.3 with placebo. In evoke+, average scores worsened by 2.2 points with semaglutide and 2.1 with placebo. Both estimated treatment differences had uncertainty intervals that included zero. The trials therefore did not show a slowing of clinical progression under the conditions studied. [1]

An experiment can find a change in a laboratory marker or an association in a database while a randomized trial finds no difference on a clinical measure. The two kinds of evidence are aimed at different questions. Observational findings about people receiving a diabetes or weight-management drug can give researchers a reason to test it in Alzheimer’s disease. Random assignment in people with diagnosed early Alzheimer’s disease gives a more direct comparison for the treatment question. [1]

The trials were discontinued after the negative clinical outcome. This result applies to the oral formulation and the population and stage of disease enrolled. It does not answer the separate question of preventing new disease in people who do not have symptoms. For someone reading across semaglutide research, the result is a reminder to keep the outcome and clinical setting attached to the evidence. An approved metabolic indication and the result of a trial in early Alzheimer’s disease are two different pieces of information about the same active molecule. [1, 2]

## Sources

1. Jeffrey L. Cummings et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. The Lancet (publication 2026-03-19). <https://pubmed.ncbi.nlm.nih.gov/41865758/>
2. U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information. Drugs@FDA (publication 2026-06). <https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s007lbl.pdf>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 032 - GLP-1 SEMA and GLP-2 TIRZ.docx; article 156; content SHA-256 853e0a59ddf7b699dbf79f311b163eec2d336e6d9a8e72a6f01d3b3c0d3cbd28.
